Experienced in Short Stature (Growth Disorders)

Dr. Gad B. Kletter

Pediatric Endocrinology
311 S L St, 
Tacoma, WA 
Experienced in Short Stature (Growth Disorders)
311 S L St, 
Tacoma, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gad Kletter is a Pediatric Endocrinologist in Tacoma, Washington. Dr. Kletter is rated as an Experienced provider by MediFind in the treatment of Short Stature (Growth Disorders). His top areas of expertise are Pediatric Growth Hormone Deficiency, Precocious Puberty, Growth Hormone Deficiency (GHD), and Type 1 Diabetes (T1D).

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Endocrinology
Licenses
Pediatrics in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Community Health
  • EPO
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

311 S L St, Tacoma, WA 98405

Additional Areas of Focus

Dr. Kletter has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drugs: MOD-4023, Somatropin
Study Phase: Phase 3
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drugs: LUM-201, rhGH Norditropin® pen
Study Phase: Phase 2
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drug: Intranasal carbetocin
Study Phase: Phase 3
An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty
An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty
Enrollment Status: Completed
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

6 Total Publications

Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 18, 2020
Similar Doctors
Experienced in Short Stature (Growth Disorders)
Dr. Catherine Pihoker
Pediatric Endocrinology | Endocrinology
Experienced in Short Stature (Growth Disorders)
Dr. Catherine Pihoker
Pediatric Endocrinology | Endocrinology
4800 Sand Point Way Ne, 
Seattle, WA 
 (29.0 miles away)
206-987-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Catherine Pihoker is a Pediatric Endocrinologist and an Endocrinologist in Seattle, Washington. Dr. Pihoker is rated as a Distinguished provider by MediFind in the treatment of Short Stature (Growth Disorders). Her top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Diabetic Ketoacidosis, and Maturity Onset Diabetes of the Young.

Experienced in Short Stature (Growth Disorders)
Dr. Britney Frazier
Pediatric Endocrinology
Experienced in Short Stature (Growth Disorders)
Dr. Britney Frazier
Pediatric Endocrinology
311 S L St, 
Tacoma, WA 
 (0.1 miles away)
253-792-6630
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Britney Frazier is a Pediatric Endocrinologist in Tacoma, Washington. Dr. Frazier is rated as an Advanced provider by MediFind in the treatment of Short Stature (Growth Disorders). Her top areas of expertise are Type 1 Diabetes (T1D), Precocious Puberty, Short Stature (Growth Disorders), and Congenital Hypothyroidism.

Experienced in Short Stature (Growth Disorders)
Dr. David Werny
Pediatric Endocrinology
Experienced in Short Stature (Growth Disorders)
Dr. David Werny
Pediatric Endocrinology
4800 Sand Point Way Ne # Ms 7.820, 
Seattle, WA 
 (28.8 miles away)
206-987-6575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Werny is a Pediatric Endocrinologist in Seattle, Washington. Dr. Werny is rated as an Experienced provider by MediFind in the treatment of Short Stature (Growth Disorders). His top areas of expertise are Hypogonadotropic Hypogonadism, Hypogonadism, Sheehan Syndrome, and Panhypopituitarism.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kletter's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile